World J Mens Health.  2013 Apr;31(1):64-69.

Effect of Transurethral Resection of the Prostate on Storage Symptoms in Patients with Benign Prostatic Hyperplasia of Less than 30 ml

• Kang YJ
• Kim KH
• Seo Y
• Lee KS

Abstract

PURPOSE
Many patients with benign prostatic hyperplasia (BPH) have not only voiding symptoms but also storage symptoms. Despite the many types of treatment that have been developed for BPH, storage symptoms persist. We conducted an assessment of the efficacy of transurethral resection of the prostate (TURP) and the change in the International Prostate Symptoms Score (IPSS) storage sub-score after the procedure according to prostate size in patients with BPH.
MATERIALS AND METHODS
Men aged 50 years or older who had BPH were enrolled in this study. 186 patients were divided into two groups according to prostate size measuring using transrectal ultrasonography: In group 1, prostate size was less than 30 ml (51 patients), and in group 2, prostate size was greater than 30 ml (135 patients). All of the patients underwent TURP. We examined whether the degree of change in the IPSS, voiding symptoms, storage symptoms, and quality of life (QoL) differed before and after TURP and according to prostate size.
RESULTS
After three months of TURP, the subjects in both groups showed significant improvement in the IPSS, voiding symptoms, storage symptoms, QoL, and maximum flow rate (p<0.05). The scores for the IPSS, voiding symptoms, storage symptoms, and QoL of group 1 and 2 after three months of TURP were 16.36, 14.25 (p=0.233), 8.21, 8.24 (p=0.980), 8.11, 5.16 (p=0.014), 2.89, and 2.10 (p=0.030), respectively.
CONCLUSIONS
TURP is an effective treatment for patients with BPH, regardless of prostate size. However, while the improvement in the storage symptoms of patients with a prostate size of less than 30 ml was not significant, it was in patients with a prostate size greater than 30 ml.

Keyword

Transurethral resection of prostate; Prostatic hyperplasia; Lower urinary tract symptoms

MeSH Terms

Aged
Humans
Lower Urinary Tract Symptoms
Male
Prostate
Prostatic Hyperplasia
Quality of Life
Transurethral Resection of Prostate

Reference

1. Irwin DE, Milsom I, Hunskaar S, Reilly K, Kopp Z, Herschorn S, et al. Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. Eur Urol. 2006. 50:1306–1314.

2. Djavan B. Lower urinary tract symptoms/benign prostatic hyperplasia: fast control of the patient's quality of life. Urology. 2003. 62:3 Suppl 1. 6–14.

3. Roehrborn CG. Current medical therapies for men with lower urinary tract symptoms and benign prostatic hyperplasia: achievements and limitations. Rev Urol. 2008. 10:14–25.

4. Lepor H, Kazzazi A, Djavan B. α-Blockers for benign prostatic hyperplasia: the new era. Curr Opin Urol. 2012. 22:7–15.

5. Wasserman NF. Benign prostatic hyperplasia: a review and ultrasound classification. Radiol Clin North Am. 2006. 44:689–710.

6. McConnell JD, Roehrborn CG, Bautista OM, Andriole GL Jr, Dixon CM, Kusek JW, et al. Medical Therapy of Prostatic Symptoms (MTOPS) Research Group. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med. 2003. 349:2387–2398.

7. Oelke M, Bachmann A, Descazeaud A, Emberton M, Gravas S, Michel MC, et al. Guidelines on the management of male lower urinary tract symptoms (LUTS), incl. benign prostatic obstruction (BPO). 2012. Arnhem: European Association of Urology.

8. Reich O, Gratzke C, Stief CG. Techniques and long-term results of surgical procedures for BPH. Eur Urol. 2006. 49:970–978.

9. Jang DG, Yoo C, Oh CY, Kim SJ, Kim SI, Kim CI, et al. Current status of transurethral prostatectomy: a Korean multicenter study. Korean J Urol. 2011. 52:406–409.

10. Kallenberg F, Hossack TA, Woo HH. Long-term followup after electrocautery transurethral resection of the prostate for benign prostatic hyperplasia. Adv Urol. 2011. 2011:359478.

11. Fitzpatrick JM. Wein AJ, Kavoussi LB, Partin AW, Novick AC, Peters CA, editors. Minimally invasive and endoscopic management of benign prostatic hyperplasia. Campbell-Walsh urology. 2012. 10th ed. Philadelphia: Saunders;2655–2694.

12. Lee KS, Kim ME, Kim SJ, Kim HK, Kim HS, Kim CI, et al. Predictive factors of the long-term medical treatment failure in benign prostatic hyperplasia. Korean J Urol. 2008. 49:826–830.

13. Welch G, Kawachi I, Barry MJ, Giovannucci E, Colditz GA, Willett WC. Distinction between symptoms of voiding and filling in benign prostatic hyperplasia: findings from the Health Professionals Follow-up Study. Urology. 1998. 51:422–427.

14. Kaplan SA, Roehrborn CG, Chapple CR, Rosen RC, Irwin DE, Kopp Z, et al. Implications of recent epidemiology studies for the clinical management of lower urinary tract symptoms. BJU Int. 2009. 103:Suppl 3. 48–57.

15. Abrams PH, Farrar DJ, Turner-Warwick RT, Whiteside CG, Feneley RC. The results of prostatectomy: a symptomatic and urodynamic analysis of 152 patients. J Urol. 1979. 121:640–642.

16. Kakizaki H, Machino R, Koyanagi T. Clinical experience in lower urinary tract symptoms. BJU Int. 2001. 88:Suppl 2. 23–26.

17. Seaman EK, Jacobs BZ, Blaivas JG, Kaplan SA. Persistence or recurrence of symptoms after transurethral resection of the prostate: a urodynamic assessment. J Urol. 1994. 152:935–937.

18. Mirone V, Imbimbo C, Longo N, Fusco F. The detrusor muscle: an innocent victim of bladder outlet obstruction. Eur Urol. 2007. 51:57–66.

19. Yoshimura K, Arai Y, Ichioka K, Terada N, Matsuta Y, Okubo K. Symptom-specific quality of life in patients with benign prostatic hyperplasia. Int J Urol. 2002. 9:485–490.

20. Hakenberg OW, Helke C, Manseck A, Wirth MP. Is there a relationship between the amount of tissue removed at transurethral resection of the prostate and clinical improvement in benign prostatic hyperplasia. Eur Urol. 2001. 39:412–417.

21. Chen SS, Hong JG, Hsiao YJ, Chang LS. The correlation between clinical outcome and residual prostatic weight ratio after transurethral resection of the prostate for benign prostatic hyperplasia. BJU Int. 2000. 85:79–82.

22. Kobayashi S, Tang R, Shapiro E, Lepor H. Characterization and localization of prostatic alpha 1 adrenoceptors using radioligand receptor binding on slide-mounted tissue section. J Urol. 1993. 150:2002–2006.

23. Oh CS, Choi KY, Park RJ. Relationship between the amount of tissue removed at transurethral resection of the prostate and clinical improvement in benign prostate hyperplasia. Korean J Urol. 2003. 44:866–870.